HAEMONETICS CORP — Director's Dealing 2018

Sep 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2018-09-17

Reporting Person: GRANADILLO PEDRO P (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-17	Common Stock	M	8196	$36.37	Acquired	41555	Direct
2018-09-17	Common Stock	M	6573	$45.45	Acquired	48128	Direct
2018-09-17	Common Stock	M	10353	$35.50	Acquired	58481	Direct
2018-09-17	Common Stock	S	1502	$108.92	Disposed	56979	Direct
2018-09-17	Common Stock	S	3696	$110.11	Disposed	53283	Direct
2018-09-17	Common Stock	S	13183	$111.33	Disposed	40100	Direct
2018-09-17	Common Stock	S	11812	$113.16	Disposed	28288	Direct
2018-09-17	Common Stock	S	631	$114.16	Disposed	27657	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-17	Non-qualified Stock Option (Right to Buy)	$36.37	M	8196	Disposed	2019-07-27	Common Stock (8196)	Direct
2018-09-17	Non-qualified Stock Option (Right to Buy)	$45.45	M	6573	Disposed	2020-07-24	Common Stock (6573)	Direct
2018-09-17	Non-qualified Stock Option (Right to Buy)	$35.50	M	10353	Disposed	2021-07-23	Common Stock (10353)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.79 to $110.55, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.92 to 111.88, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.51 to $113.35, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114 to $114.44, inclusive.

F8: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.